<?xml version='1.0' encoding='utf-8'?>
<document id="12661064"><sentence text="Timed-release formulation to avoid drug-drug interaction between diltiazem and midazolam."><entity charOffset="79-88" id="DDI-PubMed.12661064.s1.e0" text="midazolam" /></sentence><sentence text="The purpose of this study was to investigate whether the use of a timed-release (TR) drug formulation can avoid unfavorable pharmacokinetic drug-drug interactions in vivo" /><sentence text=" First, the effects of the time interval between administration of midazolam and diltiazem on the known drug-drug interaction between these drugs were investigated in dogs"><entity charOffset="67-76" id="DDI-PubMed.12661064.s3.e0" text="midazolam" /><entity charOffset="81-90" id="DDI-PubMed.12661064.s3.e1" text="diltiazem" /><pair ddi="false" e1="DDI-PubMed.12661064.s3.e0" e2="DDI-PubMed.12661064.s3.e0" /><pair ddi="false" e1="DDI-PubMed.12661064.s3.e0" e2="DDI-PubMed.12661064.s3.e1" /></sentence><sentence text=" When dogs were given midazolam orally at the same time they were orally given an aqueous diltiazem solution, the area under the plasma concentration-time curves of midazolam increased significantly compared with that of midazolam given orally in the absence of diltiazem"><entity charOffset="22-31" id="DDI-PubMed.12661064.s4.e0" text="midazolam" /><entity charOffset="165-174" id="DDI-PubMed.12661064.s4.e1" text="midazolam" /><entity charOffset="221-230" id="DDI-PubMed.12661064.s4.e2" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.12661064.s4.e0" e2="DDI-PubMed.12661064.s4.e0" /><pair ddi="false" e1="DDI-PubMed.12661064.s4.e0" e2="DDI-PubMed.12661064.s4.e1" /><pair ddi="false" e1="DDI-PubMed.12661064.s4.e0" e2="DDI-PubMed.12661064.s4.e2" /><pair ddi="false" e1="DDI-PubMed.12661064.s4.e1" e2="DDI-PubMed.12661064.s4.e1" /><pair ddi="false" e1="DDI-PubMed.12661064.s4.e1" e2="DDI-PubMed.12661064.s4.e2" /></sentence><sentence text=" However, there was no significant difference in pharmacokinetics of midazolam when the diltiazem solution was administered 1-2 h after midazolam"><entity charOffset="69-78" id="DDI-PubMed.12661064.s5.e0" text="midazolam" /><entity charOffset="88-97" id="DDI-PubMed.12661064.s5.e1" text="diltiazem" /><entity charOffset="136-145" id="DDI-PubMed.12661064.s5.e2" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.12661064.s5.e0" e2="DDI-PubMed.12661064.s5.e0" /><pair ddi="false" e1="DDI-PubMed.12661064.s5.e0" e2="DDI-PubMed.12661064.s5.e1" /><pair ddi="false" e1="DDI-PubMed.12661064.s5.e0" e2="DDI-PubMed.12661064.s5.e2" /><pair ddi="false" e1="DDI-PubMed.12661064.s5.e1" e2="DDI-PubMed.12661064.s5.e1" /><pair ddi="false" e1="DDI-PubMed.12661064.s5.e1" e2="DDI-PubMed.12661064.s5.e2" /></sentence><sentence text=" Tests on a TR formulation containing diltiazem demonstrated that the first appearance of diltiazem in plasma occurs at 2"><entity charOffset="90-99" id="DDI-PubMed.12661064.s6.e0" text="diltiazem" /></sentence><sentence text="6 +/- 0" /><sentence text="5 h in dogs" /><sentence text=" Subsequent tests showed that the plasma concentration-time profile of midazolam after concurrent oral administration of the diltiazem TR formulation was almost the same as that of midazolam administered alone"><entity charOffset="71-80" id="DDI-PubMed.12661064.s9.e0" text="midazolam" /><entity charOffset="181-190" id="DDI-PubMed.12661064.s9.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.12661064.s9.e0" e2="DDI-PubMed.12661064.s9.e0" /><pair ddi="false" e1="DDI-PubMed.12661064.s9.e0" e2="DDI-PubMed.12661064.s9.e1" /></sentence><sentence text=" These results demonstrate that a TR formulation of diltiazem can avoid the interaction between diltiazem and midazolam by creating a time interval between absorption of drugs in vivo, without the need for closely controlling the time of drug administration"><entity charOffset="52-61" id="DDI-PubMed.12661064.s10.e0" text="diltiazem" /></sentence><sentence text="" /></document>